SSG
NBIX icon

Summit Securities Group’s Neurocrine Biosciences NBIX Stock Holding History

Summit Securities Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-203
Closed -$22.5K – 1303
2025
Q1 		$22.5K Buy
+203
New +$25.7K ﹤0.01% 450
2014
Q1 		– Sell
-100
Closed -$1K – 525
2013
Q4 		$1K Buy
+100
New +$976 ﹤0.01% 460

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's NBIX Position: Q2 2025 in Review

Summit Securities Group sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 203 shares — an estimated $22.5K sold.

Summit Securities Group first reported a position in NBIX in Q4 2013 and held it in 2 quarters. The position peaked at $22.5K in Q1 2025. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Summit Securities Group reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 203 Neurocrine Biosciences shares in Q2 2025, an estimated $22.5K.
  • Summit Securities Group first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 2 quarters.
  • Summit Securities Group's Neurocrine Biosciences position peaked at $22.5K in Q1 2025.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.